Treatment Outcomes and Prognostic Factors of Medication-related Osteonecrosis of the Jaw: a Case- and Literature-based Review

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2018 Nov 9

PMID 30406491

Citations 7

Authors

Shin-Ichi Yamada

Hiroshi Kurita

Eiji Kondo

Shigeru Suzuki

Fumihiro Nishimaki

Nobuhiko Yoshimura

Masafumi Morioka

Shutaro Ishii

Takahiro Kamata

Affiliations

Soon will be listed here.

Abstract

Objectives: The purpose of this study was to investigate the treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw (MRONJ) in Japanese patients.

Patients And Methods: Among 409 cases, treatment outcomes and prognostic factors were investigated in 275 patients. In statistical analyses, the 1-year cumulative curative rate was calculated with the Kaplan-Meier method, and significance was examined with the Wilcoxon test. Cox's proportional hazards regression analysis was used for the multivariate analysis.

Results: Resolution of the disease was achieved in 137 out of 275 MRONJ patients (49.8%). One-year cumulative curative rates were 39.8% in stage 1 patients, 26.3% in stage 2, and 19.0% in stage 3. The 1-year cumulative curative rates of treatment interventions were 17.2% for conservative treatment, 34.5% for sequestrectomy, and 40.7% for extended surgery including bone resection and segmental resection. As the prognostic factors of treatment outcomes, the type of medication, stage of MRONJ, and type of surgical intervention were identified as independent factors in a multivariate analysis.

Conclusion: These results suggest that surgical interventions may lead to a good prognosis in MRONJ patients.

Clinical Relevance: This study indicated that surgical intervention for MRONJ might lead to improvement of prognosis and quality of life in MRONJ patients.

Citing Articles

Preoperative Assessment of Medication-Related Osteonecrosis of the Jaw Using [18F]fluoride Positron Emission Tomography (PET)/CT and [18F]fluorodeoxyglucose PET/MRI in Correlation with Histomorphometry and Micro-CT-A Prospective Comparative Study.

Reinert C, Pfannenberg C, Guckel B, Dittmann H, Fougere C, Nikolaou K Diagnostics (Basel). 2024; 14(4).

PMID: 38396467 PMC: 10888075. DOI: 10.3390/diagnostics14040428.

Development of Cu application using dual-energy computed tomography for detecting medication-related osteonecrosis of the jaw.

Shigenaga K, Arimoto S, Kubo M, Sato T, Hiraoka Y, Takeda D J Bone Miner Metab. 2023; 41(6):865-876.

PMID: 37897670 DOI: 10.1007/s00774-023-01467-2.

Geranylgeraniol Application in Human Osteoblasts and Osteoclasts for Reversal of the Effect of Bisphosphonates.

Jung J, Park J, Chun J, Al-Nawas B, Ziebart T, Kwon Y Life (Basel). 2023; 13(6).

PMID: 37374134 PMC: 10305301. DOI: 10.3390/life13061353.

Biodegradable magnesium implant enhances angiogenesis and alleviates medication-related osteonecrosis of the jaw in rats.

Zhu W, Guo J, Yang W, Tao Z, Lan X, Wang L J Orthop Translat. 2022; 33:153-161.

PMID: 35415073 PMC: 8965768. DOI: 10.1016/j.jot.2022.03.004.

F-Fluoride PET/CT Imaging of Medication-Related Osteonecrosis of the Jaw in Conservative Treatment-A Case Report.

Reinert C, Pfannenberg C, Gatidis S, Fougere C, Nikolaou K, Hoefert S Front Oncol. 2021; 11:700397.

PMID: 34277447 PMC: 8281890. DOI: 10.3389/fonc.2021.700397.

References

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

Migliorati C . Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003; 21(22):4253-4. DOI: 10.1200/JCO.2003.99.132. View

Marx R, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005; 63(11):1567-75. DOI: 10.1016/j.joms.2005.07.010. View

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A . Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006; 24(6):945-52. DOI: 10.1200/JCO.2005.04.2465. View

Woo S, Hellstein J, Kalmar J . Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006; 144(10):753-61. DOI: 10.7326/0003-4819-144-10-200605160-00009. View

. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76. DOI: 10.1016/j.joms.2006.11.003. View

Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

Montebugnoli L, Felicetti L, Gissi D, Pizzigallo A, Pelliccioni G, Marchetti C . Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104(4):473-7. DOI: 10.1016/j.tripleo.2007.01.008. View

Abu-Id M, Warnke P, Gottschalk J, Springer I, Wiltfang J, Acil Y . "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg. 2008; 36(2):95-103. DOI: 10.1016/j.jcms.2007.06.008. View

10.

Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu M . Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-36. PMC: 2677083. DOI: 10.1359/jbmr.080205. View

11.

Van den Wyngaert T, Claeys T, Huizing M, Vermorken J, Fossion E . Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2008; 20(2):331-6. DOI: 10.1093/annonc/mdn630. View

12.

Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E . Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008; 26(36):5904-9. DOI: 10.1200/JCO.2008.16.9300. View

13.

Pautke C, Bauer F, Tischer T, Kreutzer K, Weitz J, Kesting M . Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(3):471-6. DOI: 10.1016/j.joms.2008.09.037. View

14.

Ruggiero S, Dodson T, Assael L, Landesberg R, Marx R, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg. 2009; 67(5 Suppl):2-12. DOI: 10.1016/j.joms.2009.01.009. View

15.

Carlson E, Basile J . The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009; 67(5 Suppl):85-95. DOI: 10.1016/j.joms.2009.01.006. View

16.

Stanton D, Balasanian E . Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg. 2009; 67(5):943-50. DOI: 10.1016/j.joms.2008.12.057. View

17.

ORyan F, Khoury S, Liao W, Han M, Hui R, Baer D . Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009; 67(7):1363-72. DOI: 10.1016/j.joms.2009.03.005. View

18.

Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B . Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer. 2009; 18(4):449-60. DOI: 10.1007/s00520-009-0688-1. View

19.

Williamson R . Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg. 2009; 39(3):251-5. DOI: 10.1016/j.ijom.2009.11.014. View

20.

Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S . Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and.... J Bone Miner Metab. 2010; 28(4):365-83. DOI: 10.1007/s00774-010-0162-7. View